Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched Hearing Screening National Awareness Campaign

 
Under the patronage of Deputy Prime Minister and Health Minister Ghassan Hasbani, the Ministry of Public Health launched “Hearing Screening National Awareness Campaign” under which hearing screening will be provided in six government hospitals for free for one month and at a lower cost after the campaign. It was also agreed with thirteen private hospitals to provide screening at lower costs during the campaign.

The campaign was attended by the UNICEF Representative in Lebanon Ms. Tanya Chapuisat, the head of the Association of Private Hospitals Sleiman Haroun, physicians and concerned parties.

Minister Hasbani stated that this campaign came to cover an important health topic for all the Lebanese and fell within the principle adopted by the Ministry, which is based on the fact that “an ounce of prevention is worth a pound of cure”. He went on saying that the Ministry is the only entity to cover cochlear implants. This campaign was launched with a focus on the government hospitals and a large number of private hospitals to contribute in hearing screening in infants for more than one reason: first, the human right to enjoy good health. Second: the importance of hearing at the economic level. In fact, we always talk about economic growth, investment in infrastructure, foreign and local investments…But unfortunately, many politicians and economists forget that the citizen is the key contributor to the economy. They also forget that the healthy citizen increases productivity over a long period of time.

Promedz’s director Mr. Hady Bsat noted the importance of the private-public sector cooperation, knowing that the campaign focuses on providing the Lebanese citizen with a better quality of life and a way to enhance his productivity. “If we could detect hearing impairment or loss and provide the necessary treatment at an earlier stage, the child is Likely to enroll in ordinary schools, without the need of special services or additional costs,” he added.
UNICEF Representative in Lebanon Ms. Tanya Chapuisat noted that hearing loss affects currently about 6 in 1000 children. The early detection makes parents aware of their child’s health and welfare.

Dr. Ammar

In his statement Director General Dr. walid Ammar stated that the report issued by the world health organization in march 2017 noted that untreated hearing loss takes its toll on the global economy.
    1
ATC Name B/G Ingredients Dosage Form Price
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent 35,032,787 L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution 41,515,083 L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution L.L
D11AX01 HAIRGAINE 5 G Minoxidil - 5% 5% Solution 1,963,354 L.L
D11AX01 HAIRGROW G Minoxidil - 5% 5% Solution 1,061,636 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 18,792,549 L.L
N05AD01 HALOPERIDOL G Haloperidol - 5mg 5mg Tablet 276,448 L.L
N05AD01 HALOPERIDOL G Haloperidol - 2mg 2mg Tablet 252,130 L.L
N05AD01 HALOPERIDOL G Haloperidol - 10mg 10mg Tablet 339,160 L.L
N05AD01 HALOPERIDOL G Haloperidol - 20mg 20mg Tablet 339,160 L.L
N03AF02 HARMONIE G Oxcarbazepine - 300mg 300mg Tablet, film coated 889,496 L.L
J07BC02 HAVRIX '1440' B Hepatitis A, inactivated, whole virus - 1,440 ELISA units/ml 1,440 ELISA units/ml Injectable suspension 2,215,996 L.L
J07BC02 HAVRIX JUNIOR 720 B Hepatitis A, inactivated, whole virus - 720 ELISA units/0.5ml 720 ELISA units/0.5ml Injectable suspension 1,491,665 L.L
L01BC05 HAXANIT G Gemcitabine (HCl) - 200mg 200mg Injectable lyophilised powder 1,411,035 L.L
L01BC05 HAXANIT G Gemcitabine (HCl) - 1g 1g Injectable lyophilised powder 6,829,408 L.L
D03AX HEALIN B G ?-sitosterol - 0.25% 0.25% Ointment 849,820 L.L
J07BC02 HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED BioTech Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 0.5ml/dose 0.5ml/dose Injectable suspension 1,777,904 L.L
J07BC02 HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED BioTech Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 1ml/dose 0.5ml/dose Injectable suspension 2,257,655 L.L
R05CA12 HEDECTON COUGH G Ivy leaf soft extract - 40mg/5ml Syrup 467,657 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract (Hedera Helix) - 99mg/5ml 99mg/5ml Drops solution 384,339 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract - 37mg/5ml 37mg/5ml Syrup 309,084 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 10,000IU 10,000IU Injectable freeze dried substance+diluent L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 40,000IU 40,000IU Injectable freeze dried powder + diluent L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable freeze dried substance+diluent 940,690 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable freeze dried substance+diluent 33,852,747 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 10,000IU 10,000IU Injectable freeze dried substance+diluent 2,687,685 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 20,000IU 20,000IU Injectable freeze dried powder + diluent 5,438,531 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 40,000IU 40,000IU Injectable freeze dried powder + diluent 6,316,060 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026